Masimo Corporation (NASDAQ:MASI) Position Increased by GAMMA Investing LLC

GAMMA Investing LLC increased its position in Masimo Corporation (NASDAQ:MASI) by 58.4% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 738 shares of the medical equipment provider’s stock after purchasing an additional 272 shares during the period. GAMMA Investing LLC’s holdings in Masimo were worth $123,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of MASI. Smartleaf Asset Management LLC raised its holdings in Masimo by 31.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 60 shares during the period. EverSource Wealth Advisors LLC boosted its position in Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 64 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Masimo by 0.8% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock worth $1,622,000 after acquiring an additional 82 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Masimo by 0.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock worth $1,728,000 after acquiring an additional 83 shares during the last quarter. Finally, Orion Portfolio Solutions LLC raised its stake in shares of Masimo by 2.1% during the fourth quarter. Orion Portfolio Solutions LLC now owns 4,778 shares of the medical equipment provider’s stock worth $790,000 after buying an additional 97 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Performance

Shares of MASI stock opened at $167.67 on Friday. Masimo Corporation has a one year low of $101.61 and a one year high of $194.88. The firm has a 50-day moving average of $161.89 and a 200-day moving average of $166.46. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.17 and a quick ratio of 1.62. The company has a market cap of $9.09 billion, a P/E ratio of -18.28 and a beta of 1.19.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.12. Masimo had a negative net margin of 25.06% and a positive return on equity of 22.56%. The firm had revenue of $372.00 million during the quarter, compared to the consensus estimate of $367.79 million. During the same quarter last year, the company earned $0.77 earnings per share. The company’s revenue was down 24.5% on a year-over-year basis. Equities research analysts forecast that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Insider Buying and Selling at Masimo

In other Masimo news, COO Bilal Muhsin sold 10,000 shares of the business’s stock in a transaction on Monday, May 12th. The shares were sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the transaction, the chief operating officer directly owned 24,172 shares of the company’s stock, valued at approximately $3,946,804.16. The trade was a 29.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.70% of the company’s stock.

Wall Street Analysts Forecast Growth

MASI has been the subject of several research reports. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Thursday, April 10th. Raymond James Financial cut their price target on shares of Masimo from $204.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. Piper Sandler reiterated an “overweight” rating and issued a $200.00 price target (down previously from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Wall Street Zen downgraded shares of Masimo from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Finally, BTIG Research set a $193.00 price objective on shares of Masimo and gave the company a “buy” rating in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $191.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.